Literature DB >> 16842094

Tgf-Beta pathway as a potential target in neurodegeneration and Alzheimer's.

Tony Wyss-Coray1.   

Abstract

Alzheimer's disease (AD) is a fatal neurodegenerative disease characterized by the loss of large numbers of forebrain neurons. There are currently no effective AD treatments available and the cause of the disease is unknown in the majority of cases. Because normal neuronal maintenance and survival depends on stimulation of key signaling pathways by a number of neurotrophic factors it has been postulated that reduced signaling by or expression of these factors may promote neurodegeneration. Growing evidence suggests that the transforming growth factor-beta (TGF-beta) signaling pathway may be one such neurotrophic pathway that meets important protective and survival roles in neurons. Here I explore this evidence and discuss the pathway as a potential target for the treatment of neurodegeneration and AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16842094     DOI: 10.2174/156720506777632916

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  30 in total

1.  Transforming growth factor-β1 regulates Cdk5 activity in primary sensory neurons.

Authors:  Elias Utreras; Jason Keller; Anita Terse; Michaela Prochazkova; Michael J Iadarola; Ashok B Kulkarni
Journal:  J Biol Chem       Date:  2012-03-28       Impact factor: 5.157

Review 2.  Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Pharmacol Ther       Date:  2010-08-10       Impact factor: 12.310

3.  Meta-analysis of the transforming growth factor-β1 polymorphisms and susceptibility to Alzheimer's disease.

Authors:  Wei-wei Chang; Liu Zhang; Yue-long Jin; Ying-shui Yao
Journal:  J Neural Transm (Vienna)       Date:  2012-07-11       Impact factor: 3.575

4.  TGFβ signaling induces expression of Gadd45b in retinal ganglion cells.

Authors:  Bin Liu; Xiaoguang Sun; Genn Suyeoka; Joe G N Garcia; Yannek I Leiderman
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-05       Impact factor: 4.799

5.  TGF-beta1 blockade of microglial chemotaxis toward Abeta aggregates involves SMAD signaling and down-regulation of CCL5.

Authors:  Wei-Chao Huang; Feng-Chang Yen; Feng-Shiun Shie; Chih-Ming Pan; Young-Ji Shiao; Cheng-Ning Yang; Fong-Lee Huang; Yen-Jen Sung; Huey-Jen Tsay
Journal:  J Neuroinflammation       Date:  2010-04-29       Impact factor: 8.322

Review 6.  TGF-β1 pathway as a new target for neuroprotection in Alzheimer's disease.

Authors:  Filippo Caraci; Giuseppe Battaglia; Valeria Bruno; Paolo Bosco; Viviana Carbonaro; Maria Laura Giuffrida; Filippo Drago; Maria Angela Sortino; Ferdinando Nicoletti; Agata Copani
Journal:  CNS Neurosci Ther       Date:  2009-11-19       Impact factor: 5.243

7.  Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling.

Authors:  Min-Huei Liang; Jens R Wendland; De-Maw Chuang
Journal:  Mol Cell Neurosci       Date:  2007-11-09       Impact factor: 4.314

8.  Secreted phospholipase A2-IIA-induced a phenotype of activated microglia in BV-2 cells requires epidermal growth factor receptor transactivation and proHB-EGF shedding.

Authors:  Rubén Martín; Claudia Cordova; Maria L Nieto
Journal:  J Neuroinflammation       Date:  2012-07-02       Impact factor: 8.322

9.  Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer's Disease: Implications for the Treatment.

Authors:  Paolo Bosco; Raffaele Ferri; Maria Grazia Salluzzo; Sabrina Castellano; Maria Signorelli; Ferdinando Nicoletti; Santo Di Nuovo; Filippo Drago; Filippo Caraci
Journal:  Curr Genomics       Date:  2013-04       Impact factor: 2.236

10.  Dopaminergic agonist pramipexole improves memory and increases IL-10 production in LPS-challenged rats.

Authors:  Anita Mihaylova; Nina Doncheva; Hristina Zlatanova; Delian Delev; Mariya Ivanovska; Yvetta Koeva; Marianna Murdjeva; Ilia Kostadinov
Journal:  Iran J Basic Med Sci       Date:  2021-05       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.